Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 14/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | OXTR | P30559 | 3/20 | 0.43 |
| ▸ | IDH1 | O75874 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195691 | 0.93 | AVPR1A (0.47) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL195420 | 0.92 | AVPR1A (0.52) | AVPR1AMAPTOXTRIDH1AVPR2 | |
| SCHEMBL195254 | 0.91 | AVPR1A (0.50) | AVPR1AMAPTOXTRIDH1AVPR2 | |
| SCHEMBL195798 | 0.88 | AVPR1A (0.49) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL240317 | 0.88 | AVPR1A (0.43) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL195924 | 0.87 | AVPR1A (0.43) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL195714 | 0.87 | AVPR1A (0.48) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL195801 | 0.86 | AVPR1A (0.45) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL9983443 | 0.83 | IDH1 (0.43) | AVPR1AOXTRIDH1AVPR2 | |
| SCHEMBL196446 | 0.83 | AVPR1A (0.41) | AVPR1AOXTRIDH1AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401279-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | Vantia Limited (GB) | 2012-01-04 | — | — | EP | claimed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | claimed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | claimed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | claimed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885MAPT 4852/4885OXTR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.